Equities

Ocumetics Technology Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2QB0:FRA

Ocumetics Technology Corp

Actions
  • Price (EUR)0.33
  • Today's Change0.00 / 0.00%
  • Shares traded769.00
  • 1 Year change+100.00%
  • Beta0.4914
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ocumetics Technology Corp. is a Canada-based research and product development company. The Company specializes in adaptive lens designs. The Company is focused on developing an accommodating intraocular lens. The Ocumetics lens is an expandable intraocular lens that fits within the natural lens compartment of the eye with the objective of eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses. The Lens consists of self-adapting suspension systems that modulate curvature change. The Lens’s suspension systems are comprised of cushions that are designed to conform to unique parameters of each recipient’s eye. When ciliary muscles relax, during sleep or when the eye focuses upon distant objects, the optical interface is compressed into its high energy state by expansion of the suspension system.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-4.24m
  • Incorporated2018
  • Employees--
  • Location
    Ocumetics Technology Corp1250, 639 - 5th Avenue S.W.Calgary T2P 0M9CanadaCAN
  • Phone+1 (403) 650-7718
  • Fax+1 (403) 650-7718
  • Websitehttps://ocumetics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.